Wolverine Trading, LLC Biomarin Pharmaceutical Inc Call Options Transaction History

Wolverine Trading, LLC

$93.9 Billion
Q3 2024

Call Options

26 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$69.02 - $93.84 $2.29 Million - $3.12 Million	33,200 New	33,200 $2.33 Million
Q1 2024 May 15, 2024	BUY	$83.81 - $99.0 $1.34 Million - $1.58 Million	16,000 New	16,000 $1.4 Million
Q3 2023 Nov 15, 2023	BUY	$85.07 - $94.48 $723,095 - $803,080	8,500 Added 35.42%	32,500 $2.88 Million
Q2 2023 Aug 23, 2023	SELL	$86.68 - $100.3 $1.07 Million - $1.23 Million	-12,300 Reduced 33.88%	24,000 $2.08 Million
Q1 2023 May 15, 2023	BUY	$87.74 - $117.27 $1.31 Million - $1.75 Million	14,900 Added 69.63%	36,300 $3.46 Million
Q4 2022 Feb 14, 2023	BUY	$80.93 - $108.63 $865,951 - $1.16 Million	10,700 Added 100.0%	21,400 $2.22 Million
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $41,080 - $48,470	500 Added 4.9%	10,700 $910,000
Q2 2022 Aug 15, 2022	BUY	$71.48 - $86.85 $50,036 - $60,794	700 Added 7.37%	10,200 $856,000
Q1 2022 May 16, 2022	SELL	$74.28 - $92.69 $631,380 - $787,865	-8,500 Reduced 47.22%	9,500 $740,000
Q4 2021 Feb 14, 2022	SELL	$71.72 - $91.47 $609,620 - $777,495	-8,500 Reduced 32.08%	18,000 $1.6 Million
Q3 2021 Nov 12, 2021	SELL	$74.77 - $85.47 $119,632 - $136,752	-1,600 Reduced 5.69%	26,500 $2.04 Million
Q2 2021 Aug 06, 2021	SELL	$75.51 - $84.79 $649,386 - $729,194	-8,600 Reduced 23.43%	28,100 $2.35 Million
Q1 2021 May 14, 2021	SELL	$74.73 - $90.69 $1.76 Million - $2.14 Million	-23,600 Reduced 39.14%	36,700 $2.75 Million
Q4 2020 Feb 12, 2021	SELL	$72.61 - $90.2 $747,883 - $929,060	-10,300 Reduced 14.59%	60,300 $5.24 Million
Q3 2020 Nov 13, 2020	BUY	$71.87 - $131.03 $1.66 Million - $3.03 Million	23,100 Added 48.63%	70,600 $5.37 Million
Q2 2020 Aug 13, 2020	BUY	$79.55 - $124.22 $763,680 - $1.19 Million	9,600 Added 25.33%	47,500 $5.8 Million
Q1 2020 May 11, 2020	SELL	$71.37 - $96.85 $1.24 Million - $1.69 Million	-17,400 Reduced 31.46%	37,900 $3.13 Million
Q4 2019 Feb 12, 2020	BUY	$64.27 - $86.37 $32,134 - $43,185	500 Added 0.91%	55,300 $4.68 Million
Q3 2019 Nov 14, 2019	BUY	$67.4 - $85.11 $3.69 Million - $4.66 Million	54,800 New	54,800 $3.74 Million
Q2 2019 Aug 20, 2019	SELL	$80.35 - $93.9 $2.82 Million - $3.3 Million	-35,100 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$84.2 - $98.62 $378,900 - $443,790	-4,500 Reduced 11.36%	35,100 $3.12 Million
Q4 2018 Feb 14, 2019	BUY	$80.14 - $106.07 $1.16 Million - $1.54 Million	14,500 Added 57.77%	39,600 $3.31 Million
Q3 2018 Nov 14, 2018	BUY	$93.92 - $105.72 $695,008 - $782,328	7,400 Added 41.81%	25,100 $2.43 Million
Q1 2018 May 15, 2018	SELL	$77.67 - $92.63 $295,146 - $351,994	-3,800 Reduced 17.67%	17,700 $1.44 Million
Q4 2017 Feb 14, 2018	BUY	$80.76 - $95.13 $783,372 - $922,761	9,700 Added 82.2%	21,500 $1.92 Million
Q3 2017 Nov 15, 2017	BUY	$80.6 - $94.95 $951,079 - $1.12 Million	11,800	11,800 $1.1 Million

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

Black Rock Inc. New York, NY

22.7M
Shares

$1.51 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

19.3M
Shares

$1.28 Billion
0.02% of portfolio
Primecap Management CO Pasadena, CA

18.9M
Shares

$1.25 Billion
0.99% of portfolio
Dodge & Cox San Francisco, CA

13.9M
Shares

$921 Million
0.59% of portfolio
Capital Research Global Investors Los Angeles, CA

10.5M
Shares

$696 Million
0.16% of portfolio

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.3B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.

Account